This inventor holds 34 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Immunotherapy Research. Top assignees: Assistance Publique-Hopitaux De Paris, Sorbonne Université, National Institute of Health and Medical Research. Active years: 1996-2025.
Company Filing History:
14 out of 331 
10 out of 262 
9 out of 1,853 
Years Active: 1996-2025
Areas of Expertise:
Title: David Klatzmann: Pioneering Immunologist with Numerous Patents
Introduction:
Throughout his illustrious career, David Klatzmann has been widely recognized for his exceptional contributions to the field of immunology. With a remarkable portfolio of 31 patents and a focus on novel therapies for autoimmune and inflammatory diseases, Klatzmann's groundbreaking work has had a transformative impact on medical research and treatment. Let us delve deeper into his latest patents, career highlights, and collaborations that have shaped the field of immunology.
Latest Patents:
Among Klatzmann's recent patents, two stand out as significant contributions to the field. The first patent covers the invention of genetically modified T lymphocytes, specifically regulatory T (Treg) cells or effector T cells (Teff), which stably express interleukin-2 (IL-2) or interleukin-15 (IL-15). This composition represents a promising avenue for immunotherapy research and drug development.
His second latest patent centers on the use of low dose interleukin-2 (IL-2) for treating autoimmune-related or inflammatory disorders. This invention aims to provide effective and targeted therapies for autoimmune and inflammatory diseases, with a particular focus on type I diabetes and other related conditions. Klatzmann's work in this area holds great promise for improving the lives of individuals suffering from these debilitating conditions.
Career Highlights:
David Klatzmann's remarkable career spans various prestigious institutions. He has worked at the Universite Pierre Et Marie Curie (Paris 6), where he made significant breakthroughs in immunology and contributed to the advancement of scientific knowledge. Additionally, Klatzmann has collaborated with the Assistance Publique—Hôpitaux De Paris, a leading healthcare provider in Paris, further enhancing the translation of his research into practical applications.
Collaborations:
During his career, Klatzmann has had the privilege of working alongside renowned scientists and researchers. Notably, he has collaborated closely with esteemed colleagues such as Jean-Loup Salzmann and Eliane Piaggio. These partnerships have fostered a vibrant scientific community dedicated to tackling the complexities of immunology and developing innovative solutions for challenging diseases.
Conclusion:
David Klatzmann's exceptional contributions to immunology, as evidenced by his numerous patents and groundbreaking research, have solidified his place as a leading figure in the field. His work on genetically modified T lymphocytes and the use of low dose interleukin-2 for autoimmune diseases showcases his commitment to improving medical treatments and finding novel therapeutic solutions. As the field of immunology continues to thrive, Klatzmann's work serves as an inspiration for future researchers and offers hope for those suffering from autoimmune and inflammatory disorders.